NVCT
$8.71
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Intraday
Recent News
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders
Key Insights The considerable ownership by retail investors in Nuvectis Pharma indicates that they collectively have a...
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Nuvectis Pharma, Inc. ( NASDAQ:NVCT...
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure
Nuvectis will concentrate efforts on progressing its cancer drug NXP900 after the failure of NXP800.
Nuvectis Pharma Insiders Added US$2.50m Of Stock To Their Holdings
Multiple insiders secured a larger position in Nuvectis Pharma, Inc. ( NASDAQ:NVCT ) shares over the last 12 months...